These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 35961417)

  • 61. Mesoporous silica nanoparticles in medicine--recent advances.
    Mamaeva V; Sahlgren C; Lindén M
    Adv Drug Deliv Rev; 2013 May; 65(5):689-702. PubMed ID: 22921598
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Multifunctional mesoporous silica nanoparticles modified with tumor-shedable hyaluronic acid as carriers for doxorubicin.
    Zhang J; Sun Y; Tian B; Li K; Wang L; Liang Y; Han J
    Colloids Surf B Biointerfaces; 2016 Aug; 144():293-302. PubMed ID: 27107383
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Mesoporous Silica Nanoparticles for Targeting Subcellular Organelles.
    Gisbert-Garzarán M; Lozano D; Vallet-Regí M
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33353212
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Functionalization of mesoporous silica nanoparticles for targeting, biocompatibility, combined cancer therapies and theragnosis.
    Kuthati Y; Sung PJ; Weng CF; Mou CY; Lee CH
    J Nanosci Nanotechnol; 2013 Apr; 13(4):2399-430. PubMed ID: 23763117
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Mesoporous silica nanoparticles: facile surface functionalization and versatile biomedical applications in oncology.
    Huang R; Shen YW; Guan YY; Jiang YX; Wu Y; Rahman K; Zhang LJ; Liu HJ; Luan X
    Acta Biomater; 2020 Oct; 116():1-15. PubMed ID: 32911102
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Practical Manipulation for the Preparation of Mesoporous Silica Nanoparticles for Drug Delivery Vehicles.
    Kim M; Shim H; Na YG; Lee HK; Baek JS; Cho CW
    Curr Drug Deliv; 2023; 20(8):1206-1215. PubMed ID: 36056856
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Mesoporous silica nanoparticles: An emerging approach in overcoming the challenges with oral delivery of proteins and peptides.
    Pamshong SR; Bhatane D; Sarnaik S; Alexander A
    Colloids Surf B Biointerfaces; 2023 Dec; 232():113613. PubMed ID: 37913702
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Shape-mediated biological effects of mesoporous silica nanoparticles.
    Hao N; Li L; Tang F
    J Biomed Nanotechnol; 2014 Oct; 10(10):2508-38. PubMed ID: 25992407
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Surface functionalized mesoporous silica nanoparticles as an effective carrier for epirubicin delivery to cancer cells.
    Hanafi-Bojd MY; Jaafari MR; Ramezanian N; Xue M; Amin M; Shahtahmassebi N; Malaekeh-Nikouei B
    Eur J Pharm Biopharm; 2015 Jan; 89():248-58. PubMed ID: 25511563
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Advances in silica based nanoparticles for targeted cancer therapy.
    Yang Y; Yu C
    Nanomedicine; 2016 Feb; 12(2):317-32. PubMed ID: 26706409
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Progress in Mesoporous Silica Nanoparticles as Drug Delivery Agents for Cancer Treatment.
    Mohamed Isa ED; Ahmad H; Abdul Rahman MB; Gill MR
    Pharmaceutics; 2021 Jan; 13(2):. PubMed ID: 33498885
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Mesoporous Silica Nanoparticles in Cancer Therapy: Relevance of the Targeting Function.
    Pasqua L; Leggio A; Sisci D; Andò S; Morelli C
    Mini Rev Med Chem; 2016; 16(9):743-53. PubMed ID: 26996622
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Biocompatibility, cytotoxicity and antibacterial effects of meropenem-loaded mesoporous silica nanoparticles against carbapenem-resistant
    Memar MY; Yekani M; Ghanbari H; Shahi S; Sharifi S; Maleki Dizaj S
    Artif Cells Nanomed Biotechnol; 2020 Nov; 48(1):1354-1361. PubMed ID: 33236938
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Fluorophore-free luminescent double-shelled hollow mesoporous silica nanoparticles as pesticide delivery vehicles.
    Cao L; Zhang H; Zhou Z; Xu C; Shan Y; Lin Y; Huang Q
    Nanoscale; 2018 Nov; 10(43):20354-20365. PubMed ID: 30376015
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Nanoarchitectured prototypes of mesoporous silica nanoparticles for innovative biomedical applications.
    Kankala RK; Han YH; Xia HY; Wang SB; Chen AZ
    J Nanobiotechnology; 2022 Mar; 20(1):126. PubMed ID: 35279150
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Controlled drug delivery systems for cancer based on mesoporous silica nanoparticles.
    Iturrioz-Rodríguez N; Correa-Duarte MA; Fanarraga ML
    Int J Nanomedicine; 2019; 14():3389-3401. PubMed ID: 31190798
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Mesoporous silica nanoparticles as nanocarriers.
    Wu SH; Hung Y; Mou CY
    Chem Commun (Camb); 2011 Sep; 47(36):9972-85. PubMed ID: 21716992
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Silver Mesoporous Silica Nanoparticles: Fabrication to Combination Therapies for Cancer and Infection.
    He X; Chen F; Chang Z; Waqar K; Hu H; Zheng X; Wang Y; Dong WF; Yang C
    Chem Rec; 2022 Apr; 22(4):e202100287. PubMed ID: 35020240
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Mesoporous silica nanoparticles as carrier to overcome bacterial drug resistant barriers.
    Zhuang J; Yu Y; Lu R
    Int J Pharm; 2023 Jan; 631():122529. PubMed ID: 36563796
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Mesoporous silica nanoparticles for stimuli-responsive controlled drug delivery: advances, challenges, and outlook.
    Song Y; Li Y; Xu Q; Liu Z
    Int J Nanomedicine; 2017; 12():87-110. PubMed ID: 28053526
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.